Patents by Inventor Laxminarayan Bhat

Laxminarayan Bhat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250116091
    Abstract: A seat console assembly for a working machine includes a seat console support; a seat console body movably mounted to the seat console support and movable relative thereto between an operating position and a retracted position; a safety lever movably mounted to the seat console body and movable relative thereto between a blocking position and a non-blocking position for respectively blocking and unblocking an exit passage of the working machine when the seat console body is in the operating position; and a positioning mechanism configured to move the safety lever from the blocking to the non-blocking position in response to the seat console body being moved from the operating to the retracted position. The positioning mechanism is configured such that the safety lever is independently movable with respect to the seat console body from the blocking to the non-blocking position and/or from the non-blocking to the blocking position.
    Type: Application
    Filed: October 10, 2024
    Publication date: April 10, 2025
    Applicant: J. C. Bamford Excavators Limited
    Inventors: Dnyaneshwar Mate, Carl Denovan, Mark Prince, Atul Deshmukh, Abhijit Hodage, Laxminarayan Bhat
  • Patent number: 12053477
    Abstract: The present invention provides a method of using arylpiperazine derivatives for treating pulmonary fibrosis. The method comprises a step of administering to a pulmonary fibrosis patient in need thereof an effective amount of a compound of Formula 1, which is an arylpiperazine derivative.
    Type: Grant
    Filed: March 28, 2022
    Date of Patent: August 6, 2024
    Assignee: REVIVA PHARMACEUTICALS, INC.
    Inventor: Laxminarayan Bhat
  • Publication number: 20230061592
    Abstract: The present invention provides a method of using arylpiperazine derivatives for treating pulmonary fibrosis. The method comprises a step of administering to a pulmonary fibrosis patient in need thereof an effective amount of a compound of Formula 1, which is an arylpiperazine derivative.
    Type: Application
    Filed: March 28, 2022
    Publication date: March 2, 2023
    Inventor: Laxminarayan BHAT
  • Publication number: 20210128570
    Abstract: The present invention provides a method of using arylpiperazine derivatives for treating pulmonary fibrosis. The method comprises a step of administering to a pulmonary fibrosis patient in need thereof an effective amount of a compound of Formula 1, which is an arylpiperazine derivative.
    Type: Application
    Filed: January 7, 2021
    Publication date: May 6, 2021
    Inventor: Laxminarayan BHAT
  • Patent number: 10441590
    Abstract: The present invention provides a method of using arylpiperazine derivatives for treating pulmonary hypertension. The method comprises a step of administering to a patient in need thereof an effective amount of a compound of Formula 1, which is an arylpiperazine derivative.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: October 15, 2019
    Assignee: Reviva Pharmaceuticals, Inc.
    Inventors: Laxminarayan Bhat, Marc Cantillon, Ellen M. Wallis, Seema Rani Bhat
  • Publication number: 20190142838
    Abstract: The present invention provides a method of using arylpiperazine derivatives for treating Parkinson's disease. The method is particularly effective for treating cognitive impairment associated with Parkinson's disease. The method comprises a step of administering to a patient in need thereof an effective amount of a compound of Formula I, which is an arylpiperazine derivative.
    Type: Application
    Filed: January 14, 2019
    Publication date: May 16, 2019
    Inventors: Laxminarayan BHAT, Marc Cantillon, Seema Rani Bhat
  • Patent number: 10035761
    Abstract: The present invention provides novel phenylcycloalkylmethylamine derivatives, and methods of preparing phenylcycloalkylmethylamine derivatives. The present invention also provides methods of using phenylcycloalkylmethylamine derivatives and compositions of phenylcycloalkylmethylamine derivatives. The pharmaceutical compositions of the compounds of the present invention can be used for treating and/or preventing obesity and obesity related co-morbid indications and depression and depression related co-morbid indications.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: July 31, 2018
    Assignee: Revivia Pharmaceuticals, Inc.
    Inventors: Laxminarayan Bhat, Kouacou Adiey, Seema Rani Bhat
  • Patent number: 9975862
    Abstract: The present invention provides arylpiperazine derivatives having Formula I as shown below, which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder, and depression,
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: May 22, 2018
    Assignee: Reviva Pharmaceuticals, Inc.
    Inventors: Laxminarayan Bhat, Prabhu Prasad Mohapatra, Kouacou Adiey
  • Publication number: 20180127362
    Abstract: The present invention provides novel phenylcycloalkylmethylamine derivatives, and methods of preparing phenylcycloalkylmethylamine derivatives. The present invention also provides methods of using phenylcycloalkylmethylamine derivatives and compositions of phenylcycloalkylmethylamine derivatives. The pharmaceutical compositions of the compounds of the present invention can be used for treating and/or preventing obesity and obesity related co-morbid indications and depression and depression related co-morbid indications.
    Type: Application
    Filed: June 30, 2017
    Publication date: May 10, 2018
    Inventors: Laxminarayan BHAT, Kouacou ADIEY, Seema Rani BHAT
  • Publication number: 20180125851
    Abstract: The present invention provides a method of using arylpiperazine derivatives for treating pulmonary hypertension. The method comprises a step of administering to a patient in need thereof an effective amount of a compound of Formula 1, which is an arylpiperazine derivative.
    Type: Application
    Filed: July 7, 2017
    Publication date: May 10, 2018
    Inventors: Laxminarayan Bhat, Marc Cantillon, Ellen M. Wallis, Seema Rani Bhat
  • Publication number: 20180071298
    Abstract: The present invention provides a method of using arylpiperazine derivatives for treating behavioral and psychological symptoms in Alzheimer's disease patients. The method comprises a step of administering to a patient in need thereof an effective amount of a compound of Formula 1, which is an arylpiperazine derivative.
    Type: Application
    Filed: July 7, 2017
    Publication date: March 15, 2018
    Inventors: Laxminarayan BHAT, Marc Cantillon, Seema Rani Bhat
  • Publication number: 20180071299
    Abstract: The present invention provides a method of using arylpiperazine derivatives for treating psychosis associated with Parkinson's disease. The method comprises a step of administering to a patient in need thereof an effective amount of a compound of Formula 1, which is an arylpiperazine derivative.
    Type: Application
    Filed: July 7, 2017
    Publication date: March 15, 2018
    Inventors: Laxminarayan BHAT, Marc CANTILLON, Seema Rani BHAT
  • Patent number: 9907803
    Abstract: The present invention provides a method of using arylpiperazine derivatives for treating attention deficit hyperactivity disorder (ADHD). The method comprises a step of administering to a patient in need thereof an effective amount of a compound of Formula 1, which is an arylpiperazine derivative.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: March 6, 2018
    Assignee: REVIVA PHARMACEUTICALS, INC.
    Inventor: Laxminarayan Bhat
  • Publication number: 20170327477
    Abstract: The present invention provides arylpiperazine derivatives having Formula I as shown below, which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder, and depression,
    Type: Application
    Filed: March 27, 2017
    Publication date: November 16, 2017
    Inventors: Laxminarayan BHAT, Prabhu Prasad MOHAPATRA, Kouacou ADIEY
  • Patent number: 9787564
    Abstract: Methods and systems for determining latency in a communication network may be provided. A plurality of commands may be sent in the communication network. A response may be received for each of the plurality of commands from the communication network. A pipeline round trip time may be calculated for each of the plurality of commands based on a time of the response for each of the plurality of commands. A total round trip time for the plurality of commands may be calculated based on the calculated pipeline round trip time. A time saving may be calculated for at least one of the plurality of commands serviced locally.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: October 10, 2017
    Assignee: Cisco Technology, Inc.
    Inventors: Pankaj Kumar, Jitesh Mulchandani, Magesh Babu Nagalingam, Karthik Laxminarayan Bhat
  • Patent number: 9695116
    Abstract: The present invention provides novel phenylcycloalkylmethylamine derivatives, and methods of preparing phenylcycloalkylmethylamine derivatives. The present invention also provides methods of using phenylcycloalkylmethylamine derivatives and compositions of phenylcycloalkylmethylamine derivatives. The pharmaceutical compositions of the compounds of the present invention can be used for treating and/or preventing obesity and obesity related co-morbid indications and depression and depression related co-morbid indications.
    Type: Grant
    Filed: December 31, 2015
    Date of Patent: July 4, 2017
    Assignee: Reviva Pharmaceuticals, Inc.
    Inventors: Laxminarayan Bhat, Kouacou Adiey, Seema Rani Bhat
  • Patent number: 9604944
    Abstract: The present invention provides arylpiperazine derivatives having Formula 1a as shown below, which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder, and depression,
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: March 28, 2017
    Assignee: REVIVA PHARMACEUTICALS, INC.
    Inventors: Laxminarayan Bhat, Prabhu Prasad Mohapatra, Kouacou Adiey
  • Publication number: 20170035772
    Abstract: The present invention provides a method of using arylpiperazine derivatives for treating attention deficit hyperactivity disorder (ADHD). The method comprises a step of administering to a patient in need thereof an effective amount of a compound of Formula 1, which is an arylpiperazine derivative.
    Type: Application
    Filed: October 4, 2016
    Publication date: February 9, 2017
    Inventor: Laxminarayan BHAT
  • Publication number: 20160229821
    Abstract: The present invention provides arylpiperazine derivatives having Formula I as shown below, which can be advantageously used for treating schizophrenia and related psychoses such as acute manic, bipolar disorder, autistic disorder, and depression,
    Type: Application
    Filed: February 8, 2016
    Publication date: August 11, 2016
    Inventors: Laxminarayan BHAT, Prabhu Prasad MOHAPATRA, Kouacou ADIEY
  • Publication number: 20160115121
    Abstract: The present invention provides novel phenylcycloalkylmethylamine derivatives, and methods of preparing phenylcycloalkylmethylamine derivatives. The present invention also provides methods of using phenylcycloalkylmethylamine derivatives and compositions of phenylcycloalkylmethylamine derivatives. The pharmaceutical compositions of the compounds of the present invention can be used for treating and/or preventing obesity and obesity related co-morbid indications and depression and depression related co-morbid indications.
    Type: Application
    Filed: December 31, 2015
    Publication date: April 28, 2016
    Inventors: Laxminarayan BHAT, Kouacou ADIEY, Seema Rani BHAT